- 期刊
透析病人B型肝炎之治療
Treatment of Hepatitis B Infection in Dialysis Patients
摘要
慢性B型肝炎感染是一世界性之慢性感染症，透析病人中約1～14%得到此慢性感染。B型肝炎之治療藥物包括干擾素及口服類核苷（酸）同質物，並已使用多年且具一定成效。健保對兩大類藥物之使用有明確之規範，慢性腎臟病病人口服類核苷（酸）同質物之劑量調整也有建議，但於透析病人B型肝炎治療則經驗較少。在少數小規模之報告中，干安能使用於透析病人B型肝炎治療發現B肝病毒核酸清除率平均79%。而貝樂克則為54.5%。因此須要更多經驗佐證臨床治療效果。
並列摘要
Chronic hepatitis B infection is a chronic infectious disease in the world, the prevalence of hepatitis B infection in dialysis patient was about 1 ～ 14%.Treatment of hepatitis B infection includes interferon and oral nucleos(t)ide analogues, they have been used for years and have got some clinical effect. A clear specification was set up for these two group medications by National Health Insurance. The dose adjustment was established in chronicKidney disease patients also. But the experience of treatment of hepatitis B in dialysis patient is less. In a few small scale reports, when Lamivudine was used in hepatitis B infection in dialysis patients, the HBV DNA clearance rate was 79%. Another study showed when Entecavir was used, the HBV DNA clearance rate was 54%. Therefore more experience was needed for oral nucleos(t)ide analogues using in hepatitis B infection in dialysis patients.
延伸閱讀
- 楊培銘（1998）。慢性B型肝炎之治療。台灣醫學，2(6)，654-660。https://doi.org/10.6320/FJM.1998.2(6).08
- 黃秋錦（2003）。血液透析病人的肝炎感染：現況與治療。腎臟與透析，15(3)，141-141。https://doi.org/10.6340/KD.2003(3).09
- 吳欣吉、陳金順（2009）。透析患者之C型肝炎感染。腎臟與透析，21(1)，25-31。https://doi.org/10.6340/KD.2009(1).05
- 李柏蒼、周康茹、鍾孝民（2001）。透析患者之病毒性肝炎。腎臟與透析，13(3)，138-140。https://doi.org/10.6340/KD.2001(3).07
- 陳榜（2004）。Treatment and Prevention of Hepatitis B。中國中醫臨床醫學雜誌，10(4)，301-307。https://doi.org/10.6968/TJCCTM.200412.0301